Oncocyte is at a pivotal stage in commercializing what we expect to be an industry-transforming organ transplant rejection monitoring test. We aim to deliver proven, more affordable, faster tests ...

Lake Street initiated coverage of OncoCyte (OCX) with a Buy rating and $5 price target Oncocyte has “an ambitious plan to upend the current market for transplant rejection testing” using donor ...

OncoCyte Corp (NASDAQ: OCX) reported its Q4 2024 earnings, showcasing a strong performance in its pharma services with $1.5 million in revenue and a 40% gross margin. The company ended the year ...

As of March 19, 2025, the average one-year price target for OncoCyte is $4.21/share. The forecasts range from a low of $4.04 to a high of $4.46. The average price target represents an increase of ...

OncoCyte plans to expand its clinical trial to include approximately six U.S. centers and additional European sites, enrolling 150 matched samples to demonstrate assay efficacy. Future updates ...

OncoCyte Corp (NASDAQ: OCX) reported its Q4 2024 earnings, showcasing a strong performance in its pharma services with $1.5 million in revenue and a 40% gross margin. The company ended the year with ...

Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks ...

OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. Sell-side analysts expect that OncoCyte will post -2.57 earnings per share for the current year. Insider ...